Reply to: "Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action"
J Hepatol
.
2020 Mar;72(3):585-586.
doi: 10.1016/j.jhep.2019.11.010.
Epub 2019 Dec 20.
Authors
Kate Childs
1
,
Mary Cannon
2
,
Christopher Davis
3
,
Emma C Thompson
3
,
Geoff Dusheiko
2
,
Kosh Agarwal
2
Affiliations
1
Institute of Liver Studies, King's College Hospital Trust, London, United Kingdom. Electronic address: kate.childs@nhs.net.
2
Institute of Liver Studies, King's College Hospital Trust, London, United Kingdom.
3
MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
PMID:
31870568
DOI:
10.1016/j.jhep.2019.11.010
No abstract available
Publication types
Letter
Comment
MeSH terms
Africa South of the Sahara / epidemiology
Antiviral Agents* / therapeutic use
Genotype
Hepatitis C* / drug therapy
Hepatitis C, Chronic* / drug therapy
Humans
Substances
Antiviral Agents